The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …

Several vaccines against COVID-19 use nanoparticles to protect the antigen cargo (either
proteins or nucleic acids), increase the immunogenicity and ultimately the efficacy. The …

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to
neutralization following immunization with ancestral spike-matched vaccines. It is unclear …

A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop
post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

The vaccine and drug discovery responses to COVID-19 have worked far better than could
have been imagined. Yet by the end of 2021, more than 5 million people had died, and the …

In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid
nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of …

The emergence of SARS-CoV-2 variants and potentially other highly pathogenic
sarbecoviruses in the future highlights the need for pan-sarbecovirus vaccines. Here, we …

Abstract COVID-19, caused by SARS-CoV-2, is the most consequential pandemic of this
century. Since the outbreak in late 2019, animal models have been playing crucial roles in …

SARS-CoV-2 mRNA booster vaccines provide protection from severe disease, eliciting
strong immunity that is further boosted by previous infection. However, it is unclear whether …

Summary mRNA-1273 vaccine efficacy against SARS-CoV-2 Delta wanes over time;
however, there are limited data on the impact of durability of immune responses on …